These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

110 related articles for article (PubMed ID: 14521331)

  • 1. Viramidine, a prodrug of ribavirin, shows better liver-targeting properties and safety profiles than ribavirin in animals.
    Lin CC; Yeh LT; Vitarella D; Hong Z
    Antivir Chem Chemother; 2003 May; 14(3):145-52. PubMed ID: 14521331
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Pharmacokinetics and safety of viramidine, a prodrug of ribavirin, in healthy volunteers.
    Lin CC; Philips L; Xu C; Yeh LT
    J Clin Pharmacol; 2004 Mar; 44(3):265-75. PubMed ID: 14973309
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Ascending multiple-dose pharmacokinetics of viramidine, a prodrug of ribavirin, in adult subjects with compensated hepatitis C infection.
    Aora S; Xu C; Teng A; Peterson J; Yeh LT; Gish R; Lau D; Rossi S; Lin CC
    J Clin Pharmacol; 2005 Mar; 45(3):275-85. PubMed ID: 15703363
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Pharmacokinetics and metabolism of [14C]viramidine in rats and cynomolgus monkeys.
    Lin CC; Luu K; Lourenco D; Yeh LT
    Antimicrob Agents Chemother; 2003 Aug; 47(8):2458-63. PubMed ID: 12878505
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Remofovir mesylate: a prodrug of PMEA with improved liver-targeting and safety in rats and monkeys.
    Lin CC; Yeh LT; Vitarella D; Hong Z; Erion MD
    Antivir Chem Chemother; 2004 Nov; 15(6):307-17. PubMed ID: 15646644
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Disposition and metabolic profiles of [14C]viramidine and [14C]ribavirin in rat and monkey red blood cells and liver.
    Lin CC; Lourenco D; Xu G; Yeh LT
    Antimicrob Agents Chemother; 2004 May; 48(5):1872-5. PubMed ID: 15105147
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Viramidine demonstrates better safety than ribavirin in monkeys but not rats.
    Dadgostari S; Xu C; Yeh LT; Lin CC; Vitarella D
    Drug Chem Toxicol; 2004 Aug; 27(3):191-211. PubMed ID: 15478943
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Conversion of viramidine to ribavirin in vivo by adenosine deaminase and its inhibition by 2'-deoxycoformycin.
    Wu JZ; Yeh LT; Lin CC; Hong Z
    Antivir Chem Chemother; 2006; 17(1):33-9. PubMed ID: 16542004
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Absorption, metabolism, and excretion of [14C]viramidine in humans.
    Lin CC; Xu C; Zhu N; Yeh LT
    Antimicrob Agents Chemother; 2006 Jul; 50(7):2368-73. PubMed ID: 16801414
    [TBL] [Abstract][Full Text] [Related]  

  • 10. LC-MS/MS method for simultaneous determination of viramidine and ribavirin levels in monkey red blood cells.
    Yeh LT; Nguyen M; Dadgostari S; Bu W; Lin CC
    J Pharm Biomed Anal; 2007 Feb; 43(3):1057-64. PubMed ID: 17029670
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Effect of ribavirin, levovirin and viramidine on liver toxicological gene expression in rats.
    Fang C; Srivastava P; Lin CC
    J Appl Toxicol; 2003; 23(6):453-9. PubMed ID: 14635270
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Sensitive and specific LC-MS/MS method for the simultaneous measurements of viramidine and ribavirin in human plasma.
    Liu Y; Xu C; Yan R; Lim C; Yeh LT; Lin CC
    J Chromatogr B Analyt Technol Biomed Life Sci; 2006 Feb; 832(1):17-23. PubMed ID: 16455313
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Dual-action mechanism of viramidine functioning as a prodrug and as a catabolic inhibitor for ribavirin.
    Wu JZ; Larson G; Hong Z
    Antimicrob Agents Chemother; 2004 Oct; 48(10):4006-8. PubMed ID: 15388466
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Synthesis and evaluation of a new phosphorylated ribavirin prodrug.
    Dong SD; Lin CC; Schroeder M
    Antiviral Res; 2013 Jul; 99(1):18-26. PubMed ID: 23624267
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Safety and efficacy of viramidine versus ribavirin in ViSER2: randomized, double-blind study in therapy-naive hepatitis C patients.
    Marcellin P; Gish RG; Gitlin N; Heise J; Halliman DG; Chun E; Rodriguez-Torres M
    J Hepatol; 2010 Jan; 52(1):32-8. PubMed ID: 19913323
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Activation and deactivation of a broad-spectrum antiviral drug by a single enzyme: adenosine deaminase catalyzes two consecutive deamination reactions.
    Wu JZ; Walker H; Lau JY; Hong Z
    Antimicrob Agents Chemother; 2003 Jan; 47(1):426-31. PubMed ID: 12499231
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Pharmacokinetics and metabolism of [(14)C]ribavirin in rats and cynomolgus monkeys.
    Lin CC; Yeh LT; Luu T; Lourenco D; Lau JY
    Antimicrob Agents Chemother; 2003 Apr; 47(4):1395-8. PubMed ID: 12654676
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Phosphorylation of ribavirin and viramidine by adenosine kinase and cytosolic 5'-nucleotidase II: Implications for ribavirin metabolism in erythrocytes.
    Wu JZ; Larson G; Walker H; Shim JH; Hong Z
    Antimicrob Agents Chemother; 2005 Jun; 49(6):2164-71. PubMed ID: 15917509
    [TBL] [Abstract][Full Text] [Related]  

  • 19. In vitro and in vivo influenza virus-inhibitory effects of viramidine.
    Sidwell RW; Bailey KW; Wong MH; Barnard DL; Smee DF
    Antiviral Res; 2005 Oct; 68(1):10-7. PubMed ID: 16087250
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Taribavirin in the treatment of hepatitis C.
    Deming P; Arora S
    Expert Opin Investig Drugs; 2011 Oct; 20(10):1435-43. PubMed ID: 21854301
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.